Molecular genetics and epidemiology of epithelial ovarian cancer (Review)

Oncology Reports

Volumn 26, Issue 6, 2011, Pages 1347-1356

  Haruta, Shoji ^a   Furukawa, Naoto ^a   Yoshizawa, Yoriko ^a   Tsunemi, Taihei ^a   Nagai, Akira ^a   Kawaguchi, Ryuji ^a   Tanase, Yasuhito ^a   Yoshida, Shozo ^a   Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Epidemiology; Epithelial ovarian cancer; Genetics; Pathogenesis

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; K RAS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3 KINASE;

AGE; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CLEAR CELL CARCINOMA; DIET THERAPY; ENDOMETRIOSIS; ENVIRONMENTAL FACTOR; EPITHELIUM TUMOR; ETHNIC DIFFERENCE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; JAPAN; NONHUMAN; OVARY CANCER; PELVIS CANCER; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

DIET, HIGH-FAT; ENDOMETRIOSIS; FEMALE; GENES, NEOPLASM; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 80053468155     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1456     Document Type: Review

References (77)

1. Kurman RJ and Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443, 2010.
2. Kurman RJ and Shih IeM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 42: 918-931, 2011.
3. Goodman MT and Shvetsov YB: Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev 18: 132-139, 2009.
4. Rosenblatt KA and Thomas DB: Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 5: 933-935, 1996.
5. Seidman JD, Yemelyanova A, Zaino RJ and Kurman RJ: The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol 30: 4-11, 2011.
6. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D and Crum CP: Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 26: 4160-4165, 2008.
7. Massuger L, Roelofsen T, Ham M and Bulten J: The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. Med Hypotheses 74: 859-861, 2010.
8. McGuire V, Jesser CA and Whittemore AS: Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 84: 399-403, 2002. (Pubitemid 34211865)
9. Scully RE: Pathology of ovarian cancer precursors. J Cell Biochem (Suppl) 23: 208-218, 1995.
10. Roett MA and Evans P: Ovarian cancer: an overview. Am Fam Physician 80: 609-616, 2009.
11. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ; American Cancer Society: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
12. Aris A: Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res 3: 2, 2010.
13. Rice LW: Hormone prevention strategies for breast, endometrial and ovarian cancers. Gynecol Oncol 118: 202-207, 2010.
14. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F and McGuire WP: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 3621-3627, 2007. (Pubitemid 47372600)
15. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999. (Pubitemid 29409471)
16. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000. (Pubitemid 30331967)
17. Chan JK, Zhang M, Hu JM, Shin JY, Osann K and Kapp DS: Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol 97: 103-107, 2008. (Pubitemid 351169035)
18. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M and Schlesselman JJ: Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11: 111-117, 2000. (Pubitemid 30112009)
19. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, Nomura AM, Terada KY, Carney ME and Sobin LH: Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158: 629-638, 2003. (Pubitemid 37175510)
20. Auersperg N, Wong AS, Choi KC, Kang SK and Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255-288, 2001. (Pubitemid 32458162)
21. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW and Lee Y: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19: 3-9, 2007. (Pubitemid 46095865)
22. Varella-Garcia M: Chromosomal and genomic changes in lung cancer. Cell Adh Migr 4: 100-106, 2010.
23. Ripperger T, Gadzicki D, Meindl A and Schlegelberger B: Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 17: 722-731, 2009.
24. McLemore MR, Miaskowski C, Aouizerat BE, Chen LM and Dodd MJ: Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs 32: 281-288, 2009.
25. Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, Pettinger M, Lane DS, Lessin L, Yasmeen S, Singh B, et al: Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 99: 1534-1543, 2007. (Pubitemid 351767234)
26. Greiser CM, Greiser EM and Dören M: Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13: 453-463, 2007. (Pubitemid 47303949)
27. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S and Lidegaard O: Hormone therapy and ovarian cancer. JAMA 302: 298-305, 2009.
28. Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, Quinn MA and Green AC: Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81: 559-563, 1999. (Pubitemid 29458815)
29. Vang R, Whitaker BP, Farhood AI, Silva EG, Ro JY and Deavers MT: Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 20: 252-259, 2001. (Pubitemid 32578111)
30. Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A and Saito S: Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 25: 667-672, 2001. (Pubitemid 32423367)
31. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, Lokshin AE, Idahl A, Ohlson N, Hallmans G, et al: Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 20: 799-810, 2011.
32. Kobayashi H, Sumimoto K, Moniwa N, Imai M, Takakura K, Kuromaki T, Morioka E, Arisawa K and Terao T: Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17: 37-43, 2007. (Pubitemid 46213967)
33. Kobayashi H: Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol 14: 378-382, 2009.
34. Mandai M, Yamaguchi K, Matsumura N, Baba T and Konishi I: Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 14: 383-391, 2009.
35. Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K and Fujii S: Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 14: 32-40, 2008. (Pubitemid 351377975)
36. Kobayashi H, Kajihara H, Yamada Y, Tanase Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Naruse K, Sado T and Oi H: Risk of carcinoma in women with ovarian endometrioma. Front Biosci (Elite Ed) 3: 529-539, 2011.
37. Toyokuni S: Mysterious link between iron overload and CDKN2A/2B. J Clin Biochem Nutr 48: 46-49, 2011.
38. Toyokuni S: Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 100: 9-16, 2009.
39. Weiss NS and Peterson AS: Racial variation in the incidence of ovarian cancer in the United States. Am J Epidemiol 107: 91-95, 1978. (Pubitemid 8279964)
40. Singh P, Arunachalam I, Singh P, Tan BY, Tock EP and Ratnam SS: Ovarian cancer in Oriental women from Singapore: disease pattern and survival. Int Surg 75: 115-122, 1990. (Pubitemid 20184253)
41. Chan JK, Teoh D, Hu JM, Shin JY, Osann K and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109: 370-376, 2008.
42. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD and Gilks CB: Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29: 203-211, 2010.
43. Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C and Blaakaer J: Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer 128: 2063-2074, 2011.
44. Mink PJ, Sherman ME and Devesa SS: Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 95: 2380-2389, 2002. (Pubitemid 35351146)
45. Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J and Fuller AF: Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol 110: 336-344, 2008.
46. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, Kamura T and Nakano H: Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 77: 298-304, 2000. (Pubitemid 30317153)
47. Surprasert P, Khunamornpong S and Srisomboon J: Clinicopathological features and prognosis of Thai women with endometriosis-associated ovarian carcinoma. Asian Pac J Cancer Prev 7: 638-640, 2006.
48. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, Luchini L and Crosignani PG: Endometriosis and ovarian cancer. Am J Obstet Gynecol 169: 181-182, 1993. (Pubitemid 23223956)
49. Kawaguchi R, Tsuji Y, Haruta S, Kanayama S, Sakata M, Yamada Y, Fujita H, Saito H, Tsuneto K and Kobayashi H: Clinicopathologic features of ovarian cancer in patients with ovarian endometrioma. J Obstet Gynaecol Res 34: 872-877, 2008.
50. Jiang X, Morland SJ, Hitchcock A, Thomas EJ and Campbell IG: Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58: 1707-1712, 1998. (Pubitemid 28215097)
51. Barlow DH and Kennedy S: Endometriosis: new genetic approaches and therapy. Annu Rev Med 56: 345-356, 2005. (Pubitemid 40299787)
52. Berkley KJ, Rapkin AJ and Papka RE: The pains of endometriosis. Science 308: 1587-1589, 2005. (Pubitemid 40807498)
53. Jacoby VL, Fujimoto VY, Giudice LC, Kuppermann M and Washington AE: Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol 202: 514-521, 2010.
54. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE and Westhoff CL: Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 82: 405-414, 2004. (Pubitemid 39092042)
55. Zhao C, Wu LS and Barner R: Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer 2: 94-106, 2011.
56. Kajihara H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sado T, Oi H and Kobayashi H: Clear cell carcinoma of the ovary: Potential pathogenic mechanisms (Review). Oncol Rep 23: 1193-1203, 2010.
57. Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T and Oi H: The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 19: 471-479, 2009.
58. Gilks CB: Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol 2010: 740968, 2010.
59. Cho KR: Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med 133: 1775-1781, 2009.
60. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, et al: Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8: 17, 2008.
61. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et al: ARID1A mutations in endometriosis- associated ovarian carcinomas. N Engl J Med 363: 1532-1543, 2010.
62. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE and Papadopoulos N: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231, 2010.
63. Nunez-Cruz S, Connolly DC and Scholler N: An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses. J Vis Exp 45: 2146, 2010.
64. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D and Jacks T: Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11: 63-70, 2005. (Pubitemid 40215839)
65. Wiltshire TD, Lovejoy CA, Wang T, Xia F, O'Connor MJ and Cortez D: Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J Biol Chem 285: 14565-14571, 2010.
66. Quaye L, Tyrer J, Ramus SJ, Song H, Wozniak E, DiCioccio RA, McGuire V, Høgdall E, Høgdall C, Blaakaer J, et al: Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. PLoS One 4: e5983, 2009.
67. Johnatty SE, Beesley J, Chen X, Macgregor S, Duffy DL, Spurdle AB, deFazio A, Gava N, Webb PM and Rossing M: Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility 'hot-spot'. PLoS Genet 6: e1001016, 2010.
68. Peedicayil A, Vierkant RA, Hartmann LC, Fridley BL, Fredericksen ZS, White KL, Elliott EA, Phelan CM, Tsai YY, Berchuck A, Iversen ES Jr, et al: Risk of ovarian cancer and inherited variants in relapse-associated genes. PLoS One 5: e8884, 2010.
69. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC and Kjaer SK: A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42: 874-879, 2010.
70. Ludwig AH, Murawska M, Panek G, Timorek A and Kupryjanczyk J: Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer 16: 1005-1016, 2009.
71. Beesley J, Jordan SJ, Spurdle AB, Song H, Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, McGuire V and Whittemore AS: Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev 16: 2557-2565, 2007.
72. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E and Tsai YY: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42: 880-884, 2010.
73. Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole C, Anderson AR, Anderson S and Anton-Culver H: Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 17: 3567-3572, 2008.
74. Fan Y, Yu W, Ye P, Wang H, Wang Z, Meng Q, Duan Y, Liang X and An W: NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol 30: 241-245, 2011.
75. Li Y, Wang Y, Kang S, Wang N, Zhou RM, Duan YN, Sun DL, Qin JJ, Zhao W and Zhao L: Association of vascular endothelial growth factor gene polymorphisms with susceptibility to epithelial ovarian cancer. Int J Gynecol Cancer 20: 717-723, 2010.
76. Mann A, Hogdall E, Ramus SJ, DiCioccio RA, Hogdall C, Quaye L, McGuire V, Whittemore AS, Shah M, Greenberg D, et al: Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients. Eur J Cancer 44: 2259-2265, 2008.
77. Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-Trench G, Pearce CL, Hogdall E, Whittemore AS, McGuire V and Hogdall C: Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Hum Mol Genet 18: 2297-2304, 2009.